Search and rescue for hypotheses surviving AIM-HIGH, the niacin therapy earthquake: Still problematic after the primary publication

Journal of Clinical Lipidology

Volumn 6, Issue 4, 2012, Pages 312-317

  Brinton, Eliot A ^a  

^a Utah Lipid Center and Utah Foundation for Biomedical Research   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; CHOLESTEROL; EZETIMIBE; GEMFIBROZIL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LAROPIPRANT PLUS NICOTINIC ACID; LIPOPROTEIN A; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NICOTINIC ACID; SIMVASTATIN; TRIACYLGLYCEROL;

ADVERSE OUTCOME; ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; GLUCOSE BLOOD LEVEL; HUMAN; HYPOTHESIS; INSULIN SENSITIVITY; LIPOPROTEIN BLOOD LEVEL; LOW DRUG DOSE; MEDICAL LITERATURE; MONOTHERAPY; PATIENT COMPLIANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STROKE; THROMBOSIS; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR DISEASE;

EID: 84864277677     PISSN: 19332874     EISSN: 18764789     Source Type: Journal    
DOI: 10.1016/j.jacl.2012.03.005     Document Type: Editorial

References (51)

1. R. Altschul, and I.H. Herman Influence of oxygen inhalation on cholesterol metabolism Arch Biochem 51 1954 308 309
2. R. Altschul, A. Hoffer, and J.D. Stephen Influence of nicotinic acid on serum cholesterol in man Arch Biochem 54 1955 558 559
3. W.B. Parsons, R.W.P. Achor, K.G. Berge, B.F. McKenzie, and N.W. Barker Changes in blood lipids following prolonged administration of large doses of nicotinic acid to persons with hypercholesterolemia Proc Mayo Clin 31 1956 377 390
4. W.B. Parsons Jr., and J.H. Flinn Reduction of serum cholesterol levels and beta-lipoprotein cholesterol levels by nicotinic acid AMA Arch Intern Med 103 1959 783 790
5. C.-R. Ost, and S. Stenson Regression of atherosclerosis druing nicotinic acid therapy: a study in man by means of repeated arteriographies R. Altschul, Niacin in Vascular Disorders and Hyperlipidemia 1964 Charles C. Thomas Fort Lauderdale, FL 245 262
6. F.M. Sacks, R.C. Pasternak, C.M. Gibson, B. Rosner, and P.H. Stone Effect on coronary atherosclerosis of decrease in plasma cholesterol concentrations in normocholesterolaemic patients Lancet 344 1994 1182 1186 (Pubitemid 24323706)
7. R.H. Knopp, P. Alagona, and M. Davidson Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia Metabolism 47 1998 1097 1104 (Pubitemid 28428015)
8. L.A. Carlson Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review J Intern Med 258 2005 94 114 (Pubitemid 41025967)
9. D.H. Blankenhorn, S.A. Nessim, R.L. Johnson, M.E. Sanmarco, S.P. Azen, and L. Cashin-Hemphill Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous bypass grafts JAMA 257 1987 3233 3240 (Pubitemid 17078320)
10. G. Brown, J.J. Albers, and L.D. Fisher Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B N Engl J Med 323 1990 1289 1297
11. J.P. Kane, M.J. Malloy, T.A. Ports, N.R. Phillips, J.C. Diehl, and R.J. Havel Regression of coronary atherosclerosis during treatment of familial hypercholesterolemia with combined drug regimens JAMA 264 1990 3007 3012
12. B.G. Brown, X.Q. Zhao, and A. Chait Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease N Engl J Med 345 2001 1583 1592 (Pubitemid 33126837)
13. E.J. Whitney, R.A. Krasuski, and B.E. Personius A randomized trial of a strategy for increasing high-density lipoprotein cholesterol levels: effects on progression of coronary heart disease and clinical events Ann Intern Med 142 2005 95 104
14. D.H. Blankenhorn, S.P. Azen, and D.W. Crawford Effects of colestipol-niacin therapy on human femoral atherosclerosis Circulation 83 1991 438 447
15. D.H. Blankenhorn, R.H. Selzer, and D.W. Crawford Beneficial effects of colestipol-niacin therapy on the common carotid artery. Two- and four-year reduction of intima-media thickness measured by ultrasound Circulation 88 1993 20 28 (Pubitemid 23195428)
16. A.J. Taylor, L.E. Sullenberger, H.J. Lee, J.K. Lee, and K.A. Grace Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins Circulation 110 2004 3512 3517 (Pubitemid 39612564)
17. M. Thoenes, A. Oguchi, and S. Nagama The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome Int J Clin Pract 61 2007 1942 1948 (Pubitemid 47573105)
18. A.J. Taylor, T.C. Villines, and E.J. Stanek Extended-release niacin or ezetimibe and carotid intima-media thickness N Engl J Med 361 2009 2113 2122
19. J.M. Lee, M.D. Robson, and L.M. Yu Effects of high-dose modified-release nicotinic acid on atherosclerosis and vascular function: a randomized, placebo-controlled, magnetic resonance imaging study J Am Coll Cardiol 54 2009 1787 1794
20. Clofibrate and niacin in coronary heart disease JAMA 231 1975 360 381
21. L.A. Carlson, and G. Rosenhamer Reduction of mortality in the Stockholm Ischaemic Heart Disease secondary prevention study by combined treatment with clofibrate and nicotinic acid Acta Med Scand 223 1988 405 418
22. E. Bruckert, J. Labreuche, and P. Amarenco Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis Atherosclerosis 210 2010 353 361
23. P.L. Canner, K.G. Berge, and N.K. Wenger Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin J Am Coll Cardiol 8 1986 1245 1255 (Pubitemid 17208898)
24. S.M. Grundy, J.I. Cleeman, and C.N. Merz Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Arterioscler Thromb Vasc Biol 24 2004 E149 E161
25. The role of niacin in raising high-density lipoprotein cholesterol to reduce cardiovascular events in patients with atherosclerotic cardiovascular disease and optimally treated low-density lipoprotein cholesterol Rationale and study design. The Atherothrombosis Intervention in Metabolic syndrome with low HDL/high triglycerides: Impact on Global Health outcomes (AIM-HIGH) Am Heart J 161 2011 471 e2 477 e2
26. Treatment of HDL to Reduce the Incidence of Vascular Events HPS2-THRIVE. National Institutes of Health. Available at: http://clinicaltrials.gov/ct2/show/ NCT00461630. Accessed March 23, 2012.
27. NIH stops clinical trial on combination cholesterol treatment. National Institutes of Health, 2011. Available at: http://www.nih.gov/news/health/ may2011/nhlbi-26.htm. Accessed April 11, 2012.
28. W.E. Boden, J.L. Probstfield, and T. Anderson Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 2011 2255 2267
29. W.E. Boden Late-Breaking Clinical Trial Presentation American Heart Association Annual Scientific Sessions; 2011 2011 AMA Orlando, FL
30. M.J. Chapman, H.N. Ginsberg, and P. Amarenco Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management Eur Heart J 32 2011 1345 1361
31. J. Wink, G. Giacoppe, and J. King Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy Am Heart J 143 2002 514 518 (Pubitemid 34185184)
32. Scandinavian Simvastatin Survival Study Group Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S) Lancet 344 1994 1383 1389
33. H.B. Rubins, S.J. Robins, and D. Collins Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group N Engl J Med 341 1999 410 418 (Pubitemid 29362514)
34. M. Yokoyama, H. Origasa, and M. Matsuzaki Effects of eicosapentaenoic acid on major coronary events in hypercholesterolaemic patients (JELIS): a randomised open-label, blinded endpoint analysis Lancet 369 2007 1090 1098 (Pubitemid 46483662)
35. AIM-HIGH Halted: A Death Knell for the HDL Hypothesis? Six Experts Weigh In. New England Journal of Medicine, 2011. Available at: http://www. cardioexchange.org/aim-high-halted-a-death-knell-for-the-hdl-hypothesis/. Accessed March 23, 2012.
36. What future for niacin after AIM-HIGH? 2011. Available at: http://www.theheart.org/article/1248191.do. Accessed April 11, 2012.
37. C. Baigent, L. Blackwell, and J. Emberson Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials Lancet 376 2010 1670 1681
38. X. Zhao, L. Dong, and T. Hatsukami Magnetic resonance imaging of plaque lipid depletion during lipid therapy: a prospective assessment of efficacy and time course American College of Cardiology Annual Meeting 2009 Journal of the American College of Cardiology Orlando, FL
39. J.R. Guyton Combination regimens with statin, niacin, and intestinally active LDL-lowering drugs: alternatives to high-dose statin therapy? Curr Opin Lipidol 21 2010 372 377
40. J.R. Guyton, B.G. Brown, and S. Fazio Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia J Am Coll Cardiol 51 2008 1564 1572 (Pubitemid 351509420)
41. F. Vittone, A. Chait, J.S. Morse, B. Fish, B.G. Brown, and X.Q. Zhao Niacin plus simvastatin reduces coronary stenosis progression among patients with metabolic syndrome despite a modest increase in insulin resistance: A subgroup analysis of the HDL-Atherosclerosis Treatment Study (HATS) J Clin Lipidol 1 2007 203 210 (Pubitemid 47055291)
42. M.B. Elam, D.B. Hunninghake, and K.B. Davis Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: The ADMIT Study: A Randomized Trial JAMA 284 2000 1263 1270
43. S.M. Grundy, G.L. Vega, and M.E. McGovern Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial Arch Intern Med 162 2002 1568 1576 (Pubitemid 34765005)
44. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 2010 735 742
45. D. Preiss, S.R. Seshasai, and P. Welsh Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis JAMA 305 2011 2556 2564
46. Niaspan Prescribing Information. Physicians' Desk Reference, 2010. Available at: http://www.pdr.net/drugpages/productlabeling.aspx?mpcode=00403000. Accessed April 11, 2012.
47. AIM-HIGH Discussion. National Lipid Association, 2011. Available at: http://www.lipid.org/newcommunity/orca/topic/AIM-HIGH-Discussion.htm. Accessed March 23, 2012.
48. HPS2-THRIVE Professionals' Home Page. Available at: http://www.ctsu.ox. ac.uk/hps2-thrive/professionals.htm. Accessed March 23, 2012.
49. D. Maccubbin, H.E. Bays, and A.G. Olsson Lipid-modifying efficacy and tolerability of extended-release niacin/laropiprant in patients with primary hypercholesterolaemia or mixed dyslipidaemia Int J Clin Pract 62 2008 1959 1970
50. Five Lessons From Niaspan's Disappointing Study. 2011. Available at: http://blogs.forbes.com/harlankrumholz/2011/05/31/five-lessons-from-niaspans- disappointing-study/. Accessed March 23, 2012.
51. AIM-HIGH Study: Statement to Members. National Lipidi Association, 2011. Available at: http://www.lipid.org/pages/statement.php. Accessed March 23, 2012.